BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19396468)

  • 1. Fatal pulmonary fibrosis after rituximab administration.
    Chaumais MC; Garnier A; Chalard F; Peuchmaur M; Dauger S; Jacqz-Agrain E; Deschênes G
    Pediatr Nephrol; 2009 Sep; 24(9):1753-5. PubMed ID: 19396468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
    Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
    Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe respiratory adverse events associated with rituximab infusion.
    Kamei K; Ito S; Iijima K
    Pediatr Nephrol; 2010 Jun; 25(6):1193. PubMed ID: 20024586
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
    Smith GC
    Pediatr Nephrol; 2007 Jun; 22(6):893-8. PubMed ID: 17310362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotic syndrome and rituximab: facts and perspectives.
    Haffner D; Fischer DC
    Pediatr Nephrol; 2009 Aug; 24(8):1433-8. PubMed ID: 19495800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unusual cause of severe persistent neutropenia in a child with nephrotic syndrome.
    Kshirsagar AA; Reid CJ; Alamelu J; Sinha MD
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23365164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome.
    Spatafora M; Bellini T; Giordano C; Ghiggeri GM
    BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26661285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome.
    Kurosu N; Sugiura H; Iwasaki C; Asamiya Y; Kojima C; Moriyama T; Itabashi M; Tsukada M; Takei T; Ogawa T; Yoshida T; Uchida K; Tsuchiya K; Nitta K
    Intern Med; 2009; 48(21):1901-4. PubMed ID: 19881243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution.
    Bitzan M; Ouahed JD; Krishnamoorthy P; Bernard C
    Pediatr Nephrol; 2008 Aug; 23(8):1355-61. PubMed ID: 18351394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
    Sellier-Leclerc AL; Macher MA; Loirat C; Guérin V; Watier H; Peuchmaur M; Baudouin V; Deschênes G
    Pediatr Nephrol; 2010 Jun; 25(6):1109-15. PubMed ID: 20238230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
    Benz K; Dötsch J; Rascher W; Stachel D
    Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for childhood refractory nephrotic syndrome.
    Iijima K
    Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in steroid-dependent nephrotic syndrome.
    El Koumi M
    Iran J Kidney Dis; 2013 Nov; 7(6):502-6. PubMed ID: 24241100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.
    Grenda R; Jarmużek W; Rubik J; Piątosa B; Prokurat S
    Eur J Pediatr; 2016 Sep; 175(9):1133-1137. PubMed ID: 27364906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome.
    Bernard J; Bruel A; Allain-Launay E; Dantal J; Roussey G
    Pediatr Transplant; 2018 Jun; 22(4):e13175. PubMed ID: 29569812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.